Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia

NCT00924040 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
1
Enrollment
NIH
Sponsor class

Stopped The supply of BL22 has expired and MedImmune the sponsor is not interested in producing any new supply.

Conditions

Interventions

Sponsor

National Cancer Institute (NCI)